Close Menu

NEW YORK – OncoCyte said after the close of the market on Tuesday that its third quarter net loss rose 73 percent year over year as it prepares for 2020 launches of two lung cancer tests.

Next year, the firm plans to release a test to noninvasively assess risk in patients with lung nodules and another to predict which patients may need added chemotherapy after surgery.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.